NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Verrica Pharmaceuticals Inc. VRCA
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$35.6M
▲ 370.2% vs FY2024
EPS · FY25
$-1.68
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-240.4%
Net margin · FY25
-50.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 35.6M
Revenue, FY2025 · full 9-year series below
Revenue
Net income
The company lost 50 cents on every revenue dollar this year.
Per share
USD -1.68
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-240.4%
Return on equity, FY2025
ROE
Operating margin-34.2%
Net margin-50.3%
Return on assets-35.3%
Each USD of equity lost 240 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+57.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2025
Change, 5 years+65.0%
Change, 10 years—
The share count grew 65% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 47.1M
total assets, end of FY2025
Total assetsUSD 47.1M
EquityUSD 24.7M
CashUSD 30.1M
Gross debtUSD 0.00
Net debtUSD -30.1M
Current ratio2.59×
The company holds more cash than debt.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.0
0.0
0.0
0.0
0.0
·
·
·
·
Operating income $B
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
·
Income tax $B
0.0
0.0
0.0
0.0
·
·
·
·
·
Net income $B
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1.68
−14.78
−1.48
−0.72
−1.30
−1.71
−1.13
−1.41
−1.56
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
−240.4
−1546.6
−224.1
−67.4
−107.0
−87.1
−36.5
−50.1
·
Shares out B
0.02
0.01
0.04
0.04
0.03
0.03
0.03
0.03
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
27 of 27
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed